1. Meaning 

Commercial genome collateralization refers to the proposed use of a person's genetic information, genomic database, biological samples, or rights associated with genomic technology as security for a commercial loan, investment, or other financial obligation.

For example, a biotechnology company might seek a loan and offer its genomic database, contractual rights to use genetic information, or intellectual property in a genetic-testing platform as collateral.

The central legal question is:

Can genetic information or genome-related assets lawfully be pledged, mortgaged, charged, or subjected to enforcement by a creditor when a borrower defaults?

The answer depends on the nature of the asset, the rights held by the borrower, consent and privacy obligations, intellectual-property law, contract law, and the jurisdiction concerned.

An important distinction must be made at the outset: commercial genome collateralization is a useful analytical term, but it is not a universally recognized, standalone legal doctrine. Its legality must be assessed using existing laws governing property, secured transactions, privacy, biotechnology, and human rights.

2. Different forms of genome collateralization

How advances in genomics will change medicine in general practice | GPonline

A. Genetic data as collateral

A business attempts to pledge a database containing genetic sequences, genomic profiles, or genetic-testing results. The database may have commercial value, but the borrower's control over its use is constrained by privacy law, contractual obligations, and the rights of data subjects.

Optimizing Biobanking Practices: How to Reduce Freeze-Thaw Damage and Protect Biospecimen Integrity | Veritas Innovation

B. Biological samples as collateral

A company attempts to pledge stored blood, tissue, cells, or DNA samples. Ownership, custody, consent conditions, research restrictions, and applicable biospecimen rules determine whether a transferable property interest exists.

“Biotechnology Patents IP Challenges For Research And Pharma In India”

C. Genome-related intellectual property

A biotechnology company pledges patents, software, laboratory equipment, or contractual licensing rights associated with genomic analysis. These assets may be capable of securing a loan, subject to ownership, patentability, licence restrictions, and registration requirements.

Accreditation & Quality | SNT Biotech Lab

D. Revenue from genomic services

A company pledges receivables or future revenue from lawful genetic-testing services. This can be legally different from pledging the underlying genetic data or a person's biological identity.

The distinction is crucial because a creditor may be able to enforce a valid security interest over a company's patent or receivables without acquiring any right to sell, disclose, or independently exploit the genetic information of individuals.

3. Legal framework in India

In India, the legality of commercial genome collateralization must be examined through several interacting legal regimes.

A. Constitutional right to privacy

The leading authority is Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1.

The nine-judge Bench of the Supreme Court held that privacy is a fundamental right protected by the Constitution, particularly under Article 21 and the freedoms guaranteed by Part III.

Indian Kanoon+1

Application to genome collateralization:

Genetic information can reveal health conditions, hereditary characteristics, and biological relationships.

A commercial agreement does not automatically eliminate a person's privacy interests.

A borrower cannot necessarily transfer rights that belong to individual data subjects.

A creditor's financial interest does not, by itself, justify unrestricted access to sensitive genomic information.

The judgment did not directly decide whether a genome can be pledged as collateral. Its relevance is constitutional: commercial arrangements involving personal genetic information must be evaluated consistently with applicable privacy protections.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 provides a statutory framework for the processing of digital personal data. Its definition of personal data covers information about an identifiable individual, which can encompass identifiable genomic information.

India Code+1

Relevant provisions include:

These provisions must be read subject to their applicable commencement dates and exceptions. The Act's commencement is staggered, so not every substantive obligation should be assumed to have been operative on 2 November 2026. The official text and commencement notifications should be checked for the transaction date.

India Code+1

Legal implication: a lender should not assume that taking security over a database authorizes the lender to process, disclose, sell, or commercially exploit its identifiable genomic contents. The validity of each proposed use must be assessed separately.

C. Indian Contract Act, 1872

The Contract Act governs contractual obligations, including the validity of loan agreements, security arrangements, representations, and remedies for breach.

Important provisions include:

Section 10: requirements for enforceable contracts.

Section 23: agreements are void where their object or consideration is unlawful or falls within the statutory grounds of public policy.

Sections 73–74: compensation and stipulated damages for breach, subject to their respective requirements.

A contract purporting to grant a lender unrestricted commercial control over identifiable human genomes may encounter serious legal difficulties if its performance violates privacy rights, statutory requirements, or other applicable law.

However, the use of genomic assets in a financing transaction is not automatically unlawful merely because the transaction involves biological information. Its validity depends on the rights actually transferred or encumbered and the intended enforcement mechanism.

D. Patents Act, 1970

A biotechnology company may possess patent rights in eligible inventions involving genomic analysis, laboratory methods, or engineered biological technologies.

Section 3(c) excludes the discovery of a living thing or non-living substance occurring in nature from patentability. Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, including seeds, varieties and species, and essentially biological processes for production or propagation of plants and animals.

Consequently, a company cannot simply assume that a naturally occurring human gene or an individual's genome is a patentable asset. A patent relating to a qualifying invention is legally distinct from ownership of a person's genetic information.

A valid patent may be capable of supporting a security arrangement under the applicable property, contract, and intellectual-property rules. That does not create ownership over the individuals whose data were used in developing the invention.

E. Secured transactions and insolvency

The legal analysis also depends on the nature of the proposed collateral:

A company's receivables from genetic-testing services may be transferable or chargeable under applicable law.

Patent rights and other intellectual property may support security arrangements, subject to the relevant statutory and registration requirements.

A database may involve a mixture of copyright, contractual rights, technical infrastructure, and personal data, each with different legal characteristics.

A biological sample held by a laboratory may be subject to consent conditions, custody arrangements, research restrictions, and rules governing its permitted use.

Under the Insolvency and Bankruptcy Code, 2016, insolvency proceedings do not automatically extinguish statutory restrictions or turn a debtor's limited rights into unrestricted ownership.

Practical conclusion for India: financing a biotechnology enterprise using lawful business assets is legally distinguishable from using a person's genome itself as a freely disposable commodity. The latter raises substantially greater questions of privacy, consent, property rights, and enforceability.

4. Important case laws

The following decisions provide relevant legal principles. None should be misrepresented as a direct judicial ruling that expressly approves or prohibits all forms of commercial genome collateralization.

Case 1: Moore v. Regents of the University of California (1990)

51 Cal. 3d 120; 793 P.2d 479

Facts: John Moore's excised cells were used in research that resulted in a commercially valuable cell line. He alleged that his physician had failed to disclose relevant financial interests and asserted property-based claims concerning his cells.

Judgment: The California Supreme Court rejected Moore's conversion claim concerning his excised cells but allowed other claims, including claims based on alleged failures of disclosure, to proceed under the applicable legal principles.

California Supreme Court Resources+1

Legal principle: Commercial value arising from biological material does not automatically establish that the original donor owns every resulting research product or has a proprietary interest in it.

Application: A creditor should not assume that an individual donor's genome, an extracted sample, and a company's commercially developed genetic technology constitute a single transferable asset.

Case 2: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

569 U.S. 576

Facts: Myriad Genetics held patents relating to the BRCA1 and BRCA2 genes, which are associated with increased risks of breast and ovarian cancer.

Judgment: The US Supreme Court held that naturally occurring DNA segments were not patent-eligible merely because they had been isolated. It distinguished synthetically created complementary DNA (cDNA), which could be patent-eligible where it was not naturally occurring.

LII / Legal Information Institute

Legal principle: The commercial value of genetic discoveries does not mean that naturally occurring human genetic material is freely patentable.

Application: A lender considering genomic collateral must distinguish between naturally occurring genetic sequences, qualifying patented inventions, analytical methods, and contractual commercial rights. Patent eligibility and ownership must be established rather than presumed.

Case 3: S. and Marper v. United Kingdom (2008)

Applications nos. 30562/04 and 30566/04; Grand Chamber, 4 December 2008

Facts: The case concerned the retention of DNA samples and profiles of two people after criminal proceedings had ended without convictions.

Judgment: The European Court of Human Rights found that the blanket retention of their fingerprints, cellular samples, and DNA profiles violated Article 8 of the European Convention on Human Rights, which protects private life.

HUDOC+1

Legal principle: Genetic information is inherently sensitive, and its storage and use require appropriate legal safeguards and proportionality.

Application: A lender's enforcement of security over a genomic database should not automatically permit indefinite retention or unrestricted secondary use of personal genetic information. The case is a strong privacy-law analogy, although it concerned state retention rather than private lending.

Case 4: Greenberg v. Miami Children's Hospital Research Institute, Inc. (2003)

264 F. Supp. 2d 1064 (S.D. Fla. 2003)

Facts: Families and nonprofit organisations contributed biological samples, information, and resources to research into Canavan disease. They later challenged the commercialisation and patenting of research outcomes.

Judgment: The court dismissed several claims, including conversion claims relating to voluntarily donated samples, while allowing an unjust-enrichment claim to survive the motion to dismiss. This was not a final finding that the defendants were liable for unjust enrichment.

PubMed+1

Legal principle: Donated biological material and the commercial products developed through research are legally distinguishable; the terms and circumstances of the research relationship matter.

Application: When a biotechnology company pledges research assets, the lender must examine donor agreements, research collaboration contracts, ownership provisions, and any restrictions on commercial exploitation.

Case 5: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

(2017) 10 SCC 1

Facts: The Supreme Court considered whether privacy is constitutionally protected in India in proceedings concerning the Aadhaar identity system.

Judgment: A nine-judge Bench unanimously recognised privacy as a fundamental right.

Indian Kanoon+1

Legal principle: Privacy is integral to personal liberty and dignity. State action affecting privacy must satisfy applicable constitutional requirements.

Application: In India, the decision provides a significant constitutional foundation for scrutinising the use of identifiable genomic information in commercial arrangements. However, its direct constitutional application depends on the facts, including whether state action is involved; private transactions are also governed by applicable statutes and other laws.

5. Is genome collateralization legal?

The answer depends on precisely what the borrower proposes to pledge.

The important distinction is between security over an enterprise's lawful economic rights and security that purports to confer control over another person's body, identity, or private genetic information.

6. Major legal issues

A. Ownership and transferability

A borrower can ordinarily offer only the rights it actually possesses. Possession of a genetic database does not necessarily confer ownership of every item of information in it, nor does possession of a biological sample establish an unrestricted right to sell or transfer it.

A lender's security interest cannot normally be broader than the borrower's legally enforceable interest.

B. Informed consent and purpose limitation

Consent to medical treatment, genetic testing, or research should not automatically be interpreted as consent to collateralisation, disclosure to creditors, or commercial resale.

The relevant consent documents, statutory permissions, and restrictions must be examined individually.

C. Creditor enforcement and insolvency

Suppose a genomic-testing company defaults on a loan. A secured creditor may seek to take control of the company's assets or sell them through insolvency proceedings.

The creditor must nevertheless distinguish between:

Equipment and infrastructure that can lawfully be transferred.

Intellectual property that the company owns or is entitled to license.

Personal information that remains subject to legal restrictions.

Research samples subject to donor agreements or other conditions.

A sale of a company does not, by itself, eliminate the privacy rights or consent requirements applicable to its genomic records.

D. Discrimination and financial exploitation

Genome-based lending also raises ethical and policy concerns. For example, a lender might attempt to use a borrower's genetic predisposition to illness to determine creditworthiness, or a distressed borrower might be pressured into granting unusually broad access to genetic information.

Depending on the circumstances, such practices could raise questions involving privacy, discrimination, consumer protection, contractual fairness, and applicable financial-sector rules. Whether a particular practice is unlawful requires analysis under the relevant legislation.

7. Hypothetical legal example

Consider an Indian biotechnology company, Genomics Ltd., which seeks a ₹10 crore loan.

It proposes to offer three assets as collateral:

Its sequencing equipment.

Its patent rights in a qualifying genomic-analysis technology.

A database containing genetic profiles and health information of 50,000 individuals.

The first two assets may be capable of supporting a lawful security arrangement, subject to ownership and the applicable formalities. The third requires a separate assessment because the company may hold only limited rights to process the data for specified purposes.

If Genomics Ltd. defaults, the lender might be able to enforce security over the equipment and eligible intellectual-property rights. It cannot simply infer from that security that it may sell the identifiable genetic profiles to third parties or use them for unrelated commercial purposes.

The precise outcome would depend on the contractual documents, the data-protection provisions in force at the relevant time, the nature of the collateral, and the applicable insolvency and security laws.

8. Recommended safeguards for lawful transactions

Before accepting genome-related assets as collateral, a lender and borrower should consider the following measures.

Asset classification: Separate equipment, patents, software, receivables, databases, and physical samples.

Title verification: Establish who owns each asset and whether any licence or contractual restriction limits transfer.

Privacy assessment: Identify personal genomic information and determine the lawful basis for each proposed processing activity.

Consent review: Check whether existing consent and research agreements permit the contemplated use, disclosure, or transfer.

Enforcement limitations: Expressly restrict creditor access to identifiable genetic data unless the access is independently lawful.

Security and confidentiality: Implement access controls, encryption, audit logs, and confidentiality obligations.

Insolvency planning: Establish procedures for lawful asset transfers, continued research operations, restricted data access, and any required deletion or return of samples.

Independent legal review: Obtain advice from professionals familiar with secured transactions, biotechnology, data protection, and insolvency law.

These safeguards do not guarantee legality, but they help identify and reduce the principal risks.

9. Conclusion

Commercial genome collateralization sits at the intersection of property law, secured lending, biotechnology, privacy, intellectual property, and human dignity.

The cases of Moore, Myriad Genetics, Greenberg, S. and Marper, and Puttaswamy establish important principles concerning biological material, genetic research, patentability, privacy, and commercial exploitation. None directly creates a universal rule governing genomic collateral.

The strongest legal distinction is between pledging lawfully transferable business assets associated with genomic technology and attempting to pledge a person's genetic identity or unrestricted control over their personal genetic information.

In India, any proposed transaction should be assessed under the Constitution, applicable data-protection provisions, the Indian Contract Act, intellectual-property law, and the relevant secured-transactions and insolvency framework.

This is a general legal analysis, not a legal opinion on a specific transaction. The outcome depends on the jurisdiction, the exact asset, the agreements, and the laws in force when the security is created and enforced.